421 Kipling Street
About BridgeBio LLC
We focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. Our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting R&D with expert capabilities and placing them in a value maximizing corporate structure.
Hope through rigorous science.
84 articles with BridgeBio LLC
BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures
AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation
BridgeBio Pharma, Inc. reported financial results for the third quarter, which ended September 30, 2019, and provided recent highlights across the company’s research and development portfolio..
QED and Parent Company BridgeBio Announce Preclinical Data Supporting Tolerability and Activity of Low-dose Infigratinib in Treating Achondroplasia
Infigratinib showed improvements in nine measures of bone development in the Fgfr3[Y367C/+] mouse model of achondroplasia at a low dose
Navire Pharma, a BridgeBio subsidiary, to Present Data Showing Potential of SHP2 Inhibitor IACS-13909 in Treatment-Resistant Lung Cancer
Preclinical data shows SHP2 inhibitor enhances activity of osimertinib in EGFR-driven tumor xenografts
Eidos Therapeutics, Inc. announced that the Special Committee of its Board of Directors unanimously rejected the non-binding proposal dated August 8, 2019 from BridgeBio Pharma, Inc., the parent entity of the Company’s majority stockholder, to purchase all of the outstanding common stock of the Company not already owned by BridgeBio for a fixed exchange ratio of 1.30 shares of BridgeBio common stock for each share of Eidos common stock.
BridgeBio launched Charlotte, N.C.-based ML Bio Solutions to develop the LGMD2i asset BBP-418, a substrate supplementation therapy.
A list of the top 10 biotech IPOs from January to the end of June this year shows significant involvement in the Hong Stock exchange, with five companies based in China, and one, Frontage Holdings, operating in both the U.S. and China.
BridgeBio Pharma, Inc. has announced the pricing of its initial public offering of 20,500,000 shares of its common stock at a price to the public of $17.00 per share, as detailed in the company’s press release.
6/27/2019Two of this week’s biotech startup initial public offerings, BridgeBio and Adaptive Biotechnologies, have market values exceeding the magic $1 billion mark, and have recently launched initial public offerings (IPOs), but also increased their fundraising goals.
This week marked initial public offering news from six biopharma companies. Here’s a look.
QED Therapeutics Presents New Data on the Potential for Infigratinib to Treat Upper Tract Urothelial Carcinoma
QED Therapeutics announced the presentation of data demonstrating the clinical activity of its investigational product infigratinib in advanced or metastatic upper tract urothelial carcinoma compared to urothelial carcinoma of the bladder.
BridgeBio Pharma, Inc. announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of shares of its common stock.
BridgeBio Pharma Closes $299.2 Million Financing Round to Support Its Efforts to Target Genetic Disease at the Source
The round was co-led by existing investors KKR and Viking Global Investors.
BridgeBio Pharma LLC Signs Joint Collaboration Agreement with Cincinnati Children's to Accelerate Development of Genetic Disease Therapeutics
BridgeBio Pharma LLC and Cincinnati Children's Hospital Medical Center today announced they are entering into a research collaboration to identify and develop genetic disease therapies.
NeuroVive out-licenses targeted LHON therapy to BridgeBio Pharma's new subsidiary Fortify Therapeutics
NeuroVive Pharmaceutical AB and BridgeBio Pharma today jointly announced that BridgeBio has entered into an exclusive licensing agreement for a subset of succinate prodrug chemistry under NeuroVive's NVP015 program
BridgeBio Pharma announced the launch of CoA Therapeutics, a biopharmaceutical company developing novel small-molecules designed to increase Coenzyme-A (CoA) levels in genetic disorders where CoA deficiency is implicated.
BridgeBio Pharma Enters into Agreement to Acquire Late Stage Therapy for Ultra-Rare Disorder from Alexion; Launches Origin Biosciences to Develop and Commercialize Therapy
Promising compound has potential for treatment of Molybdenum Cofactor Deficiency Type A, an inborn error of metabolism
BridgeBio stepped in to take over the drug and also launch a subsidiary, QED Therapeutics, to drive the development of infigratinib.
The new hires will join current CEO-in-residence, Shafique Virani, M.D., who is focused on central nervous system and oncology development programs.
MD Anderson Cancer Center And BridgeBio Launch Navire Pharma To Develop Targeted Therapy For Patients With Difficult-To-Treat Cancer
BridgeBio has committed $30 million and a team of senior business managers to the company.